12/3
07:00 am
okyo
OKYO Pharma Announces Chairman and Founder Acquires Shares
Medium
Report
OKYO Pharma Announces Chairman and Founder Acquires Shares
11/21
09:09 am
okyo
OKYO Pharm Chairman and Founder acquires shares [Seeking Alpha]
High
Report
OKYO Pharm Chairman and Founder acquires shares [Seeking Alpha]
11/21
08:35 am
okyo
OKYO Pharma Announces Chairman and Founder Acquires Shares [Yahoo! Finance]
High
Report
OKYO Pharma Announces Chairman and Founder Acquires Shares [Yahoo! Finance]
11/21
08:30 am
okyo
OKYO Pharma Announces Chairman and Founder Acquires Shares
High
Report
OKYO Pharma Announces Chairman and Founder Acquires Shares
11/18
09:24 am
okyo
OKYO Pharma to Present at OIS XV in San Diego [Yahoo! Finance]
Low
Report
OKYO Pharma to Present at OIS XV in San Diego [Yahoo! Finance]
11/18
08:30 am
okyo
OKYO Pharma to Present at OIS XV in San Diego
Low
Report
OKYO Pharma to Present at OIS XV in San Diego
10/29
07:00 am
okyo
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
Medium
Report
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
10/16
08:30 am
okyo
OKYO Pharma Announces Chairman and Founder Acquires Shares
Low
Report
OKYO Pharma Announces Chairman and Founder Acquires Shares
9/23
08:07 am
okyo
OKYO Pharma (NASDAQ:OKYO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
OKYO Pharma (NASDAQ:OKYO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
9/22
08:57 am
okyo
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain [Yahoo! Finance]
Medium
Report
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain [Yahoo! Finance]
9/22
08:30 am
okyo
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
High
Report
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
9/18
06:44 am
okyo
OKYO Pharma (NASDAQ:OKYO) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
OKYO Pharma (NASDAQ:OKYO) was upgraded by analysts at Zacks Research to a "hold" rating.